Literature DB >> 19169821

Simultaneous quantification of perfusion and permeability in the prostate using dynamic contrast-enhanced magnetic resonance imaging with an inversion-prepared dual-contrast sequence.

Lutz Lüdemann1, Daniel Prochnow, Torsten Rohlfing, Tobias Franiel, Carsten Warmuth, Matthias Taupitz, Hagen Rehbein, Dirk Beyersdorff.   

Abstract

The aim of the present study was to quantify both perfusion and extravasation in the prostate to discriminate tumor from healthy tissue, which might be achieved by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) using a nonspecific low-molecular-weight contrast medium (CM). To determine extravasation as well as tissue perfusion an inversion-prepared dual-contrast sequence employing a parallel acquisition technique (PAT) was designed for interleaved acquisition of T(1)-weighted images for extravasation measurement and T(2)*-weighted images for determination of the highly concentrated bolus with a sufficiently high temporal and spatial resolution at an acceptable signal-to-noise ratio. Thirteen patients with proven prostate cancer were examined with the sequence using a combined body-array prostate coil. Before pharmacokinetic evaluation the images were intensity-corrected and, if required, motion-corrected. The pharmacokinetic model used to calculate perfusion, permeability, blood volume, interstitial volume, transit time, and vessel size index included two compartments and a correction of delay and dispersion of the arterial input function. The information provided by the dual-contrast sequence allowed application of a more elaborate model for evaluation and enabled quantification of all parameters. Peripheral prostate tumors were found to differ from peripheral healthy prostate tissue in perfusion (1.38 mL/(min cm(3)) vs. 0.23 mL/(min cm(3)), p=0.004), mean transit time (2.88 vs. 4.88 s, p=0.039), and blood volume (1.9 vs. 0.7%, p=0.019). A inversion-prepared dual-contrast sequence acquiring T(1)- and T*(2)-weighted images with sufficient temporal resolution and signal-to-noise ratio was successfully applied in patients with prostate cancer to quantify all pharmacokinetic parameters of inflow and extravasation of a low-molecular-weight inert tracer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19169821     DOI: 10.1007/s10439-009-9645-x

Source DB:  PubMed          Journal:  Ann Biomed Eng        ISSN: 0090-6964            Impact factor:   3.934


  15 in total

1.  Targeted drug delivery by high intensity focused ultrasound mediated hyperthermia combined with temperature-sensitive liposomes: computational modelling and preliminary in vivovalidation.

Authors:  Astrid Gasselhuber; Matthew R Dreher; Ari Partanen; Pavel S Yarmolenko; David Woods; Bradford J Wood; Dieter Haemmerich
Journal:  Int J Hyperthermia       Date:  2012       Impact factor: 3.914

Review 2.  Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer.

Authors:  Tobias Franiel; Bernd Hamm; Hedvig Hricak
Journal:  Eur Radiol       Date:  2010-12-24       Impact factor: 5.315

Review 3.  Vessel caliber--a potential MRI biomarker of tumour response in clinical trials.

Authors:  Kyrre E Emblem; Christian T Farrar; Elizabeth R Gerstner; Tracy T Batchelor; Ronald J H Borra; Bruce R Rosen; A Gregory Sorensen; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2014-08-12       Impact factor: 66.675

4.  Drug release kinetics of temperature sensitive liposomes measured at high-temporal resolution with a millifluidic device.

Authors:  Caitlin Burke; Matthew R Dreher; Ayele H Negussie; Andrew S Mikhail; Pavel Yarmolenko; Aakash Patel; Brenden Skilskyj; Bradford J Wood; Dieter Haemmerich
Journal:  Int J Hyperthermia       Date:  2017-12-28       Impact factor: 3.914

Review 5.  Magnetic resonance imaging: a potential tool in assessing the addition of hyperthermia to neoadjuvant therapy in patients with locally advanced breast cancer.

Authors:  Oana I Craciunescu; Donald E Thrall; Zeljko Vujaskovic; Mark W Dewhirst
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

6.  Intravoxel incoherent motion MR imaging for prostate cancer: an evaluation of perfusion fraction and diffusion coefficient derived from different b-value combinations.

Authors:  Yuxi Pang; Baris Turkbey; Marcelino Bernardo; Jochen Kruecker; Samuel Kadoury; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke
Journal:  Magn Reson Med       Date:  2012-04-09       Impact factor: 4.668

7.  Feasibility of measuring prostate perfusion with arterial spin labeling.

Authors:  Xiufeng Li; Gregory J Metzger
Journal:  NMR Biomed       Date:  2012-06-07       Impact factor: 4.044

Review 8.  Magnetic resonance in the era of molecular imaging of cancer.

Authors:  John C Gore; H Charles Manning; C Chad Quarles; Kevin W Waddell; Thomas E Yankeelov
Journal:  Magn Reson Imaging       Date:  2011-04-27       Impact factor: 2.546

9.  Signal-to-noise ratio, contrast-to-noise ratio and pharmacokinetic modeling considerations in dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Xin Li; Wei Huang; William D Rooney
Journal:  Magn Reson Imaging       Date:  2012-07-15       Impact factor: 2.546

10.  Predicting clinically significant prostate cancer from quantitative image features including compressed sensing radial MRI of prostate perfusion using machine learning: comparison with PI-RADS v2 assessment scores.

Authors:  David Jean Winkel; Hanns-Christian Breit; Bibo Shi; Daniel T Boll; Hans-Helge Seifert; Christian Wetterauer
Journal:  Quant Imaging Med Surg       Date:  2020-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.